Science-advisor
REGISTER info/FAQ
Login
username
password
     
forgot password?
register here
 
Research articles
  search articles
  reviews guidelines
  reviews
  articles index
My Pages
my alerts
  my messages
  my reviews
  my favorites
 
 
Stat
Members: 3645
Articles: 2'501'711
Articles rated: 2609

19 April 2024
 
  » pubmed » pmid15457249

 Article overview


Lung cancer: intragenic ERBB2 kinase mutations in tumours
Philip Stephens ; Chris Hunter ; Graham Bignell ; Sarah Edkins ; Helen Davies ; Jon Teague ; Claire Stevens ; Sarah O’Meara ; Raffaella Smith ; Adrian Parker ; Andy Barthorpe ; Matthew Blow ; Lisa Brackenbury ; Adam Butler ; Oliver Clarke ; Jennifer Cole ; Ed Dicks ; Angus Dike ; Anja Drozd ; Ken Edwards ; Simon Forbes ; Rebecca Foster ; Kristian Gray ; Chris Greenman ; Kelly Halliday ; Katy Hills ; Vivienne Kosmidou ; Richard Lugg ; Andy Menzies ; Janet Perry ; Robert Petty ; Keiran Raine ; Lewis Ratford ; Rebecca Shepherd ; Alexandra Small ; Yvonne Stephens ; Calli Tofts ; Jennifer Varian ; Sofie West ; Sara Widaa ; Andrew Yates ; Francis Brasseur ; Colin S Cooper ; Adrienne M Flanagan ; Margaret Knowles ; Suet Y Leung ; David N Louis ; Leendert H J Looijenga ; Bruce Malkowicz ; Marco A Pierotti ; Bin Teh ; Georgia Chenevix-Trench ; Barbara L Weber ; Siu T Yuen ; Grace Harris ; Peter Goldstraw ; Andrew G Nicholson ; P Andrew Futreal ; Richard Wooster ; Michael R Stratton ;
Date 30 Sep 2004
Journal Nature, 431 (7008), 525-6
AbstractThe protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.
Source PubMed, pmid15457249 doi: 10.1038/431525b
Services Forum | Review | Favorites   
 
Visitor rating: did you like this article? no 1   2   3   4   5   yes

No review found.
 Did you like this article?

This article or document is ...
important:
of broad interest:
readable:
new:
correct:
Global appreciation:

  Note: answers to reviews or questions about the article must be posted in the forum section.
Authors are not allowed to review their own article. They can use the forum section.

browser Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)






ScienXe.org
» my Online CV
» Free


News, job offers and information for researchers and scientists:
home  |  contact  |  terms of use  |  sitemap
Copyright © 2005-2024 - Scimetrica